Department of Nephrology, the Affiliated Hospital of Nantong University, Nantong, China.
Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6472. doi: 10.26355/eurrev_202307_33113.
The article "Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways", by N.-F. Guo, Y.-J. Cao, X. Chen, Y. Zhang, Y.-P. Fan, J. Liu, X.-L. Chen published in Eur Rev Med Pharmacol Sci 2019; 23 (9): 4017-4026. DOI: 10.26355/eurrev_201905_17832-PMID: 31115031 has been retracted by the Editor in Chief for the following reasons: This paper has been questioned on PubPeer (https://pubpeer.com/publications/983F02C9C18817139AE18497C359FA). In particular, concerns were raised about Figures 2A and 5A as the figures result to overlap with previously published papers. The Editorial Office has contacted the corresponding author of the article to provide a reply to the comments on PubPeer and check the raw data. Still, the journal has yet to receive a reply. Therefore, considering the comments released on PubPeer and the lack of response from authors, the Editor in Chief no longer relies on the data presented and decided to withdraw the manuscript. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/17832.
文章“利西那肽通过激活 wNF-κB/TNF-α 和 TGF-β/Smad 通路保护阿霉素诱导的肾纤维化”，由 N.-F. 郭、Y.-J. 曹、X. 陈、Y. 张、Y.-P. 范、J. 刘、X.-L. 陈发表在 2019 年的《欧洲医学与药理学评论》上，doi:10.26355/eurrev_201905_17832-PMID:31115031 已被主编撤回，原因如下：这篇论文在 PubPeer 上受到质疑 (https://pubpeer.com/publications/983F02C9C18817139AE18497C359FA)。特别是，人们对图 2A 和 5A 提出了质疑，因为这些图片与以前发表的论文存在重叠。编辑部已联系文章的通讯作者，要求他对 PubPeer 上的评论做出回应，并检查原始数据。然而，该杂志尚未收到回复。因此，考虑到 PubPeer 上发布的评论以及作者缺乏回应，主编不再依赖所提供的数据，并决定撤回该手稿。出版商对由此造成的任何不便表示歉意。https://www.europeanreview.org/article/17832.
